Variant Bio Launches Inference, the World’s First Agentic AI Genomic Drug Discovery Platform

Variant Bio has launched Inference, an agentic genomic drug discovery platform designed to help pharmaceutical R&D teams identify and validate therapeutic targets using human genetic and multi-omic data. The platform is supported by seven years of development, over $100M in investment, and Variant Bio’s proprietary global genomic datasets and active drug development programs.